Drug Type Antibody drug conjugate (ADC) |
Synonyms TRS 005, TRS005 |
Target |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), Tubulin inhibitors |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationBreakthrough Therapy (CN) |
Molecular FormulaC11H22N4O4 |
InChIKeyAGGWFDNPHKLBBV-YUMQZZPRSA-N |
CAS Registry159858-33-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Hodgkin's lymphoma refractory | Phase 2 | - | - | |
Recurrent Non-Hodgkin Lymphoma | Phase 2 | - | - | |
CD20 Positive B-Cell Non-Hodgkin Lymphoma | Phase 1 | CN | 24 Aug 2020 | |
CD20 positive Diffuse Large B-Cell Lymphoma | IND Approval | CN | 10 Apr 2024 |
Phase 1 | 40 | wtdtsctxuw(secwqwoooq) = 34.1% of pts npqxudvgyv (qjtxhkazlx ) View more | - | 10 Sep 2022 |